NPHLA Tracker · Clinical trials (ClinicalTrials.gov)
Clinical Trial Tracker: Metabolic & Aesthetic Medicine
Clinical trials followed in metabolic and aesthetic medicine — obesity and incretin therapies, neurotoxins, dermal fillers, regenerative treatments and hair restoration — with each study’s status, phase and latest registry update.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
- Records
- 187
- Changed in 7 days
- 0
- Latest record
- Jurisdiction
- International / multiple
Records
187 recordsInvestigational therapies
Every therapy studied in a clinical trial is investigational and not approved for the use being studied. A trial’s phase and status describe the study, not whether the product works.
| Record | Status | Phase | Sponsor | Jurisdiction | Date | Source | Last checked |
|---|---|---|---|---|---|---|---|
| ACHIEVE-3: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With MetforminNCT06045221Conditions: Type 2 Diabetes. Interventions: Orforglipron; Semaglutide | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06045221 (opens in a new tab)Primary source | System checked NPHLA updated |
| Topical Rifamycin SV for Wound Healing After Sapphire FUE Hair TransplantationNCT07155408Conditions: Androgenetic Alopecia; Wound Healing. Interventions: Povidone-Iodine 10%; Rifamycin SV Sodium | Completed | Not applicable | Elif Asena KANTARCI | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07155408 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effectiveness of Platelet-rich Plasma Treatment of Knee OsteoarthritisNCT05825105Conditions: Knee Osteoarthritis. Interventions: Platelet-Rich Plasma | Completed | Phase 2 | Universidad Nacional de Entre Rios | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05825105 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-OSA: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT06649045Conditions: OSA; Overweight or Obesity. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06649045 (opens in a new tab)Primary source | System checked NPHLA updated |
| First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671NCT07815678Conditions: Obesity. Interventions: ACCG-2671; Placebo | Recruiting | Phase 1 / Phase 2 | Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07815678 (opens in a new tab)Primary source | System checked NPHLA updated |
| SOLIS-1: A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932Conditions: Overweight; Obesity; Overweight and/or Obesity; Overweight or Obesity; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseas…. Interventions: PF-08653945; PF-08653944; Placebo | Active, not recruiting | Phase 2 | Pfizer | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07575932 (opens in a new tab)Primary source | System checked NPHLA updated |
| TrichoscopyDM2: Hair Changes in Females With Type 2 Diabetes Clinical and Trichoscopic ExaminationNCT07817277Conditions: Diabete Mellitus; Female Androgenetic Alopecia; Dermoscopy | Not yet recruiting | Phase not stated | Al-Azhar University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07817277 (opens in a new tab)Primary source | System checked NPHLA updated |
| IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsNCT07793019Conditions: Overweight; Healthy Participants; Obesity. Interventions: Orforglipron; Matching Placebo; IBI3042 | Recruiting | Phase 1 | Innovent Biologics (Suzhou) Co. Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07793019 (opens in a new tab)Primary source | System checked NPHLA updated |
| Topical Multivitamin Serum for Skin HeathNCT07368686Conditions: Aesthetic. Interventions: Microneedeling with topical application of VAMP(TM) ADVANCED Topical Multivitamin Serum | Completed | Phase 4 | Erevna Innovations Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07368686 (opens in a new tab)Primary source | System checked NPHLA updated |
| Acupuncture of Different Treatment Frequency in Chronic Plantar FasciitisNCT06284993Conditions: Plantar Fasciitis, Chronic. Interventions: electroacupuncture(more frequent); electroacupuncture(less frequent) | Recruiting | Not applicable | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06284993 (opens in a new tab)Primary source | System checked NPHLA updated |
| The Evira Study: Additional Support During Obesity TreatmentNCT06836284Conditions: Childhood Obesity; Treatment Adherence. Interventions: Digi-physical treatment tool, Evira; Obesity medication with liraglutide or semaglutide | Recruiting | Not applicable | Karolinska Institutet | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06836284 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086Conditions: Obesity. Interventions: CagriSema (Cagrilintide B + semaglutide I); Low Energy Diet | Active, not recruiting | Phase 1 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07184086 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869Conditions: Diabetes Mellitus, Type 2; Diabetic Peripheral Neuropathy. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Completed | Phase 2 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06797869 (opens in a new tab)Primary source | System checked NPHLA updated |
| RAMBO: The Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432Conditions: Obesity. Interventions: Cagrilintide; Semaglutide; Placebo cagrilintide; Placebo semaglutide | Recruiting | Phase 1 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07010432 (opens in a new tab)Primary source | System checked NPHLA updated |
| PLATINUM EU: A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)NCT07210463Conditions: Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholine Release Inhibitors; Membrane Transpor…. Interventions: NT 201; NT 201 Placebo | Active, not recruiting | Phase 3 | Merz Aesthetics GmbH | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07210463 (opens in a new tab)Primary source | System checked NPHLA updated |
| PLATINUM US: A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United StatesNCT07122193Conditions: Neuromuscular Agents; Peripheral Nervous System Agents; Physiological Effects of Drugs; Acetylcholine Release Inhibitors; Membrane Transpor…. Interventions: NT 201; NT 201 Placebo | Active, not recruiting | Phase 3 | Merz North America, Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07122193 (opens in a new tab)Primary source | System checked NPHLA updated |
| Botox in HS: Botulinum Toxin Blockade of Neuronal Signals to Immune Cells as a Novel Treatment for Hidradenitis SuppurativaNCT07756346Conditions: Hidradenitis Suppurativa (HS). Interventions: Botulinum Toxin A (Allergan, Inc, Irvine CA); Placebo | Not yet recruiting | Phase 2 | University of Massachusetts, Worcester | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07756346 (opens in a new tab)Primary source | System checked NPHLA updated |
| REIMAGINEYOUNG: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613Conditions: Diabetes Mellitus, Type 2. Interventions: CagriSema (Cagrilintide B and Semaglutide I); Placebo matched to CagriSema (Cagrilintide B and Semaglutide I) | Recruiting | Phase 3 | Novo Nordisk A/S | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07282613 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842Conditions: Overweight; Type 2 Diabetes; Obesity. Interventions: Petrelintide; Placebo | Completed | Phase 2 | Zealand Pharma | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06926842 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar LinesNCT07756580Conditions: Glabellar Lines. Interventions: AGN-151586; BOTOX | Recruiting | Phase 1 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07756580 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Pilot Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial AlopeciaNCT04764331Conditions: Central Centrifugal Cicatricial Alopecia. Interventions: Revian Red All LED cap | Recruiting | Not applicable | Wake Forest University Health Sciences | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT04764331 (opens in a new tab)Primary source | System checked NPHLA updated |
| KDKR26: Dual Modality Treatment of Androgenic Alopecia With KeraFactor® Solution and Revian® LED Light TherapyNCT07810504Conditions: Androgenic Alopecia; Female Pattern Hair Loss; Hair Loss. Interventions: Scalp Stimulating Serum; Red Light Hair Growth Cap; Placebo scalp-stimulating serum | Recruiting | Not applicable | K. Kay Durairaj, MD, FACS, A Medical Corporation | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07810504 (opens in a new tab)Primary source | System checked NPHLA updated |
| AGA: PRP Combined With Botulinum Toxin Type A Injection for the Treatment of Androgenetic Alopecia: A StudyNCT07335367Conditions: Androgenetic Alopecia (AGA). Interventions: Injection of PRP combined with Botulinum Toxin Type A into the alopecic area(s); PRP-only injection into the alopecic a… | Completed | Phase 2 | Nanfang Hospital, Southern Medical University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07335367 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study to Investigate the Safety and Efficacy of YY003 in Adults With Moderate to Severe Glabellar LinesNCT06481475Conditions: Moderate to Severe Glabellar Lines. Interventions: YY003; Vehicle Control | Completed | Phase 2 | Chongqing Claruvis Pharmaceutical Co., Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06481475 (opens in a new tab)Primary source | System checked NPHLA updated |
| MONA: Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic AlopeciaNCT07516561Conditions: Alopecia, Androgenetic. Interventions: APSMNF 1; APSMNF 2; Eniagor® | Not yet recruiting | Phase 3 | Apsen Farmaceutica S.A. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07516561 (opens in a new tab)Primary source | System checked NPHLA updated |
| Efficacy and Safety of Two Hair Supplements in Men With Androgenic AlopeciaNCT07806474Conditions: Androgenic Alopecia; Healthy Adult Male. Interventions: formulation of green tea leaf extract, bamboo shoot extract and selenium-enriched yeast; formulation of grape seed extr… | Not yet recruiting | Not applicable | Activ'inside | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07806474 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-2: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 DiabetesNCT05872620Conditions: Obesity; Overweight; Type 2 Diabetes. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05872620 (opens in a new tab)Primary source | System checked NPHLA updated |
| ACHIEVE-1: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise AloneNCT05971940Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05971940 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic AlopeciaNCT06916793Conditions: Androgenetic Alopecia. Interventions: CKD-843 dose#1; CKD-843 dose#2; Placebo of CKD-843 dose; Dutasteride Capsules; Placebo of Dutasteride Capsule | Recruiting | Phase 3 | Chong Kun Dang Pharmaceutical | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06916793 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Adults With and Without Androgenetic AlopeciaNCT07317544Conditions: Androgenetic Alopecia (AGA); Healthy Volunteers - Male and Female. Interventions: SAD IV Dose 1 - 150mg ABS201 IV Single Dose; Placebo IV; ABS-201 SC Multiple Doses; Placebo SC Injection | Recruiting | Phase 1 / Phase 2 | Absci Pty Ltd. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07317544 (opens in a new tab)Primary source | System checked NPHLA updated |
| This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo ControlNCT06981936Conditions: Micronutrient Deficiencies. Interventions: Balance Tablet; Control (placebo) | Completed | Phase 4 | General Committee of Teaching Hospitals and Institutes, Egypt | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06981936 (opens in a new tab)Primary source | System checked NPHLA updated |
| Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Androgenic AlopeciaNCT07373054Conditions: Androgenic Alopecia. Interventions: Topical Minoxidil; Electric Microneedling; Traditional Exosome Lyophilized Powder; Innovative Exosome Lyophilized Powder | Completed | Not applicable | Fujian Medical University Union Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07373054 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair RegrowthNCT07588243Conditions: Androgenic Alopecia. Interventions: Low Level Laser Therapy | Active, not recruiting | Not applicable | CynosureLutronic | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07588243 (opens in a new tab)Primary source | System checked NPHLA updated |
| PATHS-T2D: PATHS-T2D: A Recall-by-Genotype Study of Physiologic and Pharmacologic ResponsesNCT07739537Conditions: Diabete Type 2; Pharmacogenomic Drug Interaction. Interventions: Orforglipron | Not yet recruiting | Phase 4 | Massachusetts General Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07739537 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study to Assess Participant Satisfaction After Jawline and Neck TreatmentNCT07794891Conditions: Jawline and Neck Appearance. Interventions: OnabotulinumtoxinA; SKINVIVE; VOLUX; VOLUMA | Not yet recruiting | Phase 4 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07794891 (opens in a new tab)Primary source | System checked NPHLA updated |
| Botulinum Toxin Type A for Wound Healing After Laparoscopic ColectomyNCT07795463Conditions: Surgical Wound Healing; Botulinum Toxin, Type A. Interventions: Botulinum toxin type A (Botox®, Allergan) | Recruiting | Not applicable | Pham Ngoc Thach University of Medicine | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07795463 (opens in a new tab)Primary source | System checked NPHLA updated |
| BoTox Into the Sternocleidomastoid Muscles (SCM)NCT06903975Conditions: Neck Muscle Issue. Interventions: prabotulinumtoxinA-xvfs | Recruiting | Phase 4 | Boston Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06903975 (opens in a new tab)Primary source | System checked NPHLA updated |
| AI-09 In Subjects With Glabellar Lines, GL-101NCT05565950Conditions: Glabellar Frown Lines. Interventions: AI-09; Vehicle | Completed | Phase 1 / Phase 2 | Eirion Therapeutics Inc. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05565950 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-CN: A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health ProblemsNCT07790861Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Not yet recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07790861 (opens in a new tab)Primary source | System checked NPHLA updated |
| GLIDE-HF: GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF RegistryNCT07787936Conditions: Heart Failure With Preserved Ejection Fraction; Obesity; Diastolic Heart Failure; Pulmonary Hypertension; Iron Deficiency. Interventions: GLP-1 / GIP receptor agonist | Not yet recruiting | Phase not stated | Miedziowe Centrum Zdrowia SA | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07787936 (opens in a new tab)Primary source | System checked NPHLA updated |
| Impact of Dysport on PMFF Donor ScarNCT07720726Conditions: Skin Cancer Excision Site; Basal Cell Carcinoma; Squamous Cell Carcinoma; Melanoma. Interventions: Abobotulinumtoxin-A; Control- Saline injection | Not yet recruiting | Phase 4 | Vanderbilt University Medical Center | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07720726 (opens in a new tab)Primary source | System checked NPHLA updated |
| Study of DWP450 in Japanese Subjects With Glabellar LinesNCT07783763Conditions: Glabellar Lines. Interventions: DWP450 20 U; 0.9% Saline Solution 0.5 mL | Not yet recruiting | Phase 3 | Daewoong Pharmaceutical Co. LTD. | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07783763 (opens in a new tab)Primary source | System checked NPHLA updated |
| Effect of Liraglutide in Obese Women With Polycystic Ovary SyndromeNCT05965908Conditions: Polycystic Ovary. Interventions: liraglutide; Metformin | Completed | Phase 3 | Beni-Suef University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05965908 (opens in a new tab)Primary source | System checked NPHLA updated |
| MMP US P3 416: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle ProminenceNCT06387394Conditions: Masseter Muscle Prominence. Interventions: BOTOX; Placebo | Completed | Phase 3 | AbbVie | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06387394 (opens in a new tab)Primary source | System checked NPHLA updated |
| A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related ComorbiditiesNCT06672939Conditions: Obesity; Overweight. Interventions: Orforglipron; Placebo | Recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT06672939 (opens in a new tab)Primary source | System checked NPHLA updated |
| TRIUMPH-1: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066Conditions: Obesity; Overweight; Osteoarthritis, Knee; Obstructive Sleep Apnea. Interventions: Retatrutide; Placebo | Completed | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05929066 (opens in a new tab)Primary source | System checked NPHLA updated |
| Microneedling for Androgenic Alopecia: a Clinical StudyNCT07580521Conditions: Androgenic Alopecia. Interventions: Microneedling monotherapy without drugs | Active, not recruiting | Not applicable | Taipei Medical University WanFang Hospital | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07580521 (opens in a new tab)Primary source | System checked NPHLA updated |
| EXO-MINO: Exosome Injection Versus Topical Minoxidil for Androgenetic AlopeciaNCT07776015Conditions: Androgenetic Alopecia; Exosomes. Interventions: exosomes injection; Topical Minoxidil 5% | Completed | Not applicable | Tanta University | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07776015 (opens in a new tab)Primary source | System checked NPHLA updated |
| PROBIO-GLP1: Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA TreatmentNCT07213323Conditions: Obesity &Amp; Overweight; Digestive Disorders. Interventions: Probiotics (Natural product); Placebo | Recruiting | Not applicable | Hospices Civils de Lyon | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT07213323 (opens in a new tab)Primary source | System checked NPHLA updated |
| ATTAIN-1: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesNCT05869903Conditions: Obesity; Overweight; Overweight or Obesity. Interventions: Orforglipron; Placebo | Active, not recruiting | Phase 3 | Eli Lilly and Company | Not applicable | Last update posted | ClinicalTrials.gov (U.S. National Library of Medicine): ClinicalTrials.gov record NCT05869903 (opens in a new tab)Primary source | System checked NPHLA updated |
How is this tracker compiled?
The Intelligence pipeline queries the ClinicalTrials.gov API (version 2) for two broad searches — obesity and incretin therapies, and aesthetic and regenerative medicine (botulinum toxin, dermal fillers, polynucleotides, exosomes, platelet-rich plasma) — and for every topic with a trial query, on the schedule set in the Source Registry. Each study is stored with its registry fields as published. Changes in overall status and newly posted results are recorded with the date the pipeline detected them.
This tracker lists every tracked study whose last registry update falls within the past 365 days, newest first. Nothing in the table is edited by hand.
Selection: ClinicalTrials.gov studies followed by Trial Watch dated within the last 365 days.
What does it cover?
Studies on ClinicalTrials.gov — from the United States and other countries — that match the configured searches, from the date tracking began. Studies registered elsewhere, described with other terms, or not updated in the last year are not included.
What are its limitations?
Registry data is supplied by sponsors and may be incomplete or out of date. Inclusion reflects search terms, not clinical importance. Every therapy in a trial is investigational for the use being studied. Not medical advice.
How often is it updated?
Registry searches run every 6 to 12 hours, as configured in the Source Registry.
System checked is the last time an automated check of the underlying official sources succeeded — it is not a human review. Editorially reviewed appears only when an editor has reviewed this tracker. Each row shows its own check: an automated system check or an editor’s verification.
Data origin: NPHLA analysis of public data. Professional reference only — not medical, legal or regulatory advice. Always confirm a record in its primary source. Spotted an error? Tell us.